ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年09月03日 16時00分
Source:
Eisai
エーザイ、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ」使用目的又は効果の一部削除の承認について
東京, 2018年09月03日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、日本において、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ(R)」(高度管理医療機器、以下 本品)について、使用目的又は効果の一部削除が承認され、使用目的又は効果が「多血性腫瘍(子宮筋腫を除く)を有する患者に対する動脈塞栓療法」となりましたことをお知らせします。
今回の使用目的又は効果の一部削除の承認は、実臨床上、本品は「子宮筋腫」及び「動静脈奇形」に対して使用されないことから、関連学会に確認の上、当局と相談し、当該適応に係る使用目的又は効果の取り下げの一部変更承認申請を行っていたことに基づくものです。
当社は、本使用目的又は効果の一部削除に際し、医療関係者の皆様への適切な情報提供に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201876.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Apr 01, 2025 12:25 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
Fujitsu and Macquarie University partner to help address critical shortage of machine learning engineers
Mar 31, 2025 09:28 JST
ForexIGO by Avenix Fzco Enhances Automated Trading with Dual-Asset Precision
Mar 29, 2025 22:30 JST
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 22:51 JST
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
NEC and COEDO Brewery develop the second edition of "The taste of life created by brewers and AI -- Agentic AI x Craft Beer"
Mar 28, 2025 13:08 JST
More Latest Release >>
Related Release
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
More Press release >>